These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28194113)

  • 1. Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.
    Li J; Zheng J; Wang S; Lau HK; Fathi A; Wang Q
    Front Physiol; 2017; 8():15. PubMed ID: 28194113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
    Ban K; Noyan-Ashraf MH; Hoefer J; Bolz SS; Drucker DJ; Husain M
    Circulation; 2008 May; 117(18):2340-50. PubMed ID: 18427132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.
    Bistola V; Lambadiari V; Dimitriadis G; Ioannidis I; Makrilakis K; Tentolouris N; Tsapas A; Parissis J
    Heart Fail Rev; 2018 May; 23(3):377-388. PubMed ID: 29383638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.
    Guglielmi V; Sbraccia P
    Eat Weight Disord; 2017 Jun; 22(2):231-240. PubMed ID: 28040864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DPP4 enhances inhibitory synaptic transmission through activating the GLP-1/GLP-1R signaling pathway in a rat model of febrile seizures.
    Zhang Y; Liu Y; Xu J; Sun Q; Yu F; Cheng J; Peng B; Liu W; Xiao Z; Yin J; Han S; He X
    Biochem Pharmacol; 2018 Oct; 156():78-85. PubMed ID: 30086287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cardiovascular Biology of Glucagon-like Peptide-1.
    Drucker DJ
    Cell Metab; 2016 Jul; 24(1):15-30. PubMed ID: 27345422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
    Verge D; López X
    Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
    Baggio LL; Ussher JR; McLean BA; Cao X; Kabir MG; Mulvihill EE; Mighiu AS; Zhang H; Ludwig A; Seeley RJ; Heximer SP; Drucker DJ
    Mol Metab; 2017 Nov; 6(11):1339-1349. PubMed ID: 29107282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl Peptidase-4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress.
    Zhu E; Hu L; Wu H; Piao L; Zhao G; Inoue A; Kim W; Yu C; Xu W; Bando YK; Li X; Lei Y; Hao CN; Takeshita K; Kim WS; Okumura K; Murohara T; Kuzuya M; Cheng XW
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study.
    Ravassa S; Beaumont J; Huerta A; Barba J; Coma-Canella I; González A; López B; Díez J
    Free Radic Biol Med; 2015 Apr; 81():1-12. PubMed ID: 25595459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
    Baggio LL; Drucker DJ
    Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular actions of incretin-based therapies.
    Ussher JR; Drucker DJ
    Circ Res; 2014 May; 114(11):1788-803. PubMed ID: 24855202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.